Avandia, Actos Comparative Safety Evaluation "Not Novel," FDA Says
Executive Summary
FDA used the Avandia advisory committee to defend its view that marketing withdrawal decisions can be based on safety comparisons to other drugs approved for the same condition
You may also be interested in...
Avandia Shows FDA Discomfort With Meta-Analyses, Observational Studies In Decision-Making
The strong, continued resistance by FDA Center for Drug Evaluation and Research officials to rely on meta-analyses and observational studies as the basis for removing Avandia from the market suggests it will take time for the agency to become comfortable using the active surveillance system envisioned under the Sentinel Initiative in regulatory decision-making.
Avandia Shows FDA Discomfort With Meta-Analyses, Observational Studies In Decision-Making
The strong, continued resistance by FDA Center for Drug Evaluation and Research officials to rely on meta-analyses and observational studies as the basis for removing Avandia from the market suggests it will take time for the agency to become comfortable using the active surveillance system envisioned under the Sentinel Initiative in regulatory decision-making.
Avandia Advisory Committee Sees New Role For REMS As Research Tool
FDA advisory committee members who favor continued availability of GlaxoSmithKline's Avandia (rosiglitazone) with a Risk Evaluation and Mitigation Strategy seem to be hopeful the new regulatory tool can be used for an even broader purpose - providing answers needed to justify keeping the drug on the market